Trending Now
NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) To Continue ANA001 Phase 2/3 Clinical...
NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) has announced the review of safety data by an independent Data Monitoring Committee for 36 patients that were treated...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
TSLA stock (NASDAQ:TSLA) may be headed to double digits after missing...
Another bad news for TSLA investors and bull traders. Today, Tesla (NASDAQ:TSLA) reported fourth-quarter deliveries of 405,278. Although this was a record...
MAKE IT MODERN
LATEST REVIEWS
Alkido Pharma Inc. (NASDAQ:AIKI) Announce Updates From Cogia BioTech Efforts To...
Alkido Pharma Inc. (NASDAQ:AIKI) and its research partner, Cogia BioTech Ltd, have delivered important updates in their efforts to expedite the study of Pancreatic...
MAKE IT MODERN
PERFORMANCE TRAINING
GOOGL stock chart technicals with layoffs could spark a rally
Alphabet Inc (NASDAQ:GOOGL) last traded at $98.02. Earnings are approaching at the end of the month and this will be a binary...
Futures turn green after the Iran saga
The Geopolitical uncertainty has simmered down, for the moment and The SPY moved up yesterday but has since fallen in premarket having...
Fate Therapeutics Inc. (NASDAQ:FATE) Reports Revenue Of $7.6 Million in Q3 2020 And Progress...
Fate Therapeutics Inc. (NASDAQ:FATE) has announced its Q3 financial results and provided business highlights for the three months ended September 30, 2020. Revenue in...
Kadmon Holdings Inc. (NYSE:KDMN) Initiate Dosing In Phase I KD033 Study In Solid Tumors...
Kadmon Holdings Inc. (NYSE:KDMN) announced the dosing of the first patient in its first phase clinical study evaluating KD033in metastatic or locally advanced solid...
Seres Therapeutics Inc (NASDAQ:MCRB) Will Report SER-109 Phase 3 Study Topline Data in August...
Seres Therapeutics Inc (NASDAQ:MCRB) (STI) reported a drop of 51.75% YoY to $6.45 million in Q2 2020.
Business update
STI expects to post SER-109 Phase 3...
MAKE IT MODERN
